Format
Items per page
Sort by

Send to:

Choose Destination

Results: 1 to 20 of 883

1.

Neural tissue regeneration in experimental brain injury model with channeled scaffolds of acrylate copolymers.

Martínez-Ramos C, Gómez-Pinedo U, Esparza MA, Soria JM, Barcia JA, Pradas MM.

Neurosci Lett. 2015 May 14. pii: S0304-3940(15)00378-X. doi: 10.1016/j.neulet.2015.05.021. [Epub ahead of print]

PMID:
25980992
2.

Immune checkpoint modulation for non-small cell lung cancer.

Soria JC, Marabelle A, Brahmer JR, Gettinger S.

Clin Cancer Res. 2015 May 15;21(10):2256-62. doi: 10.1158/1078-0432.CCR-14-2959.

PMID:
25979932
3.

Systematic review and meta-analysis of phase I/II targeted therapy combined with radiotherapy in patients with glioblastoma multiforme: quality of report, toxicity, and survival.

Dos Santos MA, Pignon JP, Blanchard P, Lefeuvre D, Levy A, Touat M, Louvel G, Dhermain F, Soria JC, Deutsch E, Le Teuff G.

J Neurooncol. 2015 May 15. [Epub ahead of print]

PMID:
25975195
4.

Human Basal Tear Peptidome Characterization by CID, HCD, and ETD Followed by in Silico and in Vitro Analyses for Antimicrobial Peptide Identification.

Azkargorta M, Soria J, Ojeda C, Guzmán F, Acera A, Iloro I, Suárez T, Elortza F.

J Proteome Res. 2015 May 20. [Epub ahead of print]

PMID:
25946035
5.

A simplified interventional mapping system (SIMS) for the selection of combinations of targeted treatments in non-small cell lung cancer.

Lazar V, Rubin E, Depil S, Pawitan Y, Martini JF, Gomez-Navarro J, Yver A, Kan Z, Dry JR, Kehren J, Validire P, Rodon J, Vielh P, Ducreux M, Galbraith S, Lehnert M, Onn A, Berger R, Pierotti MA, Porgador A, Pramesh CS, Ye DW, Carvalho AL, Batist G, Le Chevalier T, Morice P, Besse B, Vassal G, Mortlock A, Hansson J, Berindan-Neagoe I, Dann R, Haspel J, Irimie A, Laderman S, Nechushtan H, Al Omari AS, Haywood T, Bresson C, Soo KC, Osman I, Mata H, Lee JJ, Jhaveri K, Meurice G, Palmer G, Lacroix L, Koscielny S, Eterovic KA, Blay JY, Buller R, Eggermont A, Schilsky RL, Mendelsohn J, Soria JC, Rothenberg M, Scoazec JY, Hong WK, Kurzrock R.

Oncotarget. 2015 Apr 3. [Epub ahead of print]

6.

Rociletinib in EGFR-mutated non-small-cell lung cancer.

Sequist LV, Soria JC, Goldman JW, Wakelee HA, Gadgeel SM, Varga A, Papadimitrakopoulou V, Solomon BJ, Oxnard GR, Dziadziuszko R, Aisner DL, Doebele RC, Galasso C, Garon EB, Heist RS, Logan J, Neal JW, Mendenhall MA, Nichols S, Piotrowska Z, Wozniak AJ, Raponi M, Karlovich CA, Jaw-Tsai S, Isaacson J, Despain D, Matheny SL, Rolfe L, Allen AR, Camidge DR.

N Engl J Med. 2015 Apr 30;372(18):1700-9. doi: 10.1056/NEJMoa1413654.

PMID:
25923550
7.

Subtype Classification of Lung Adenocarcinoma Predicts Benefit From Adjuvant Chemotherapy in Patients Undergoing Complete Resection.

Tsao MS, Marguet S, Le Teuff G, Lantuejoul S, Shepherd FA, Seymour L, Kratzke R, Graziano SL, Popper HH, Rosell R, Douillard JY, Le-Chevalier T, Pignon JP, Soria JC, Brambilla EM.

J Clin Oncol. 2015 Apr 27. pii: JCO.2014.58.8335. [Epub ahead of print]

PMID:
25918286
8.

Challenges in Initiating and Conducting Personalized Cancer Therapy Trials: Perspectives from WINTHER, a Worldwide Innovative Network (WIN) Consortium Trial.

Rodon J, Soria JC, Berger R, Batist G, Tsimberidou A, Bresson C, Lee JJ, Rubin E, Onn A, Schilsky RL, Miller WH Jr, Eggermont AM, Mendelsohn J, Lazar V, Kurzrock R.

Ann Oncol. 2015 Apr 23. pii: mdv191. [Epub ahead of print]

PMID:
25908602
9.

'Statistical controversies in clinical research': a new series in Annals of Oncology.

Soria JC, Buyse M.

Ann Oncol. 2015 Apr 22. pii: mdv158. [Epub ahead of print] No abstract available.

PMID:
25904726
10.

Pembrolizumab for the Treatment of Non-Small-Cell Lung Cancer.

Garon EB, Rizvi NA, Hui R, Leighl N, Balmanoukian AS, Eder JP, Patnaik A, Aggarwal C, Gubens M, Horn L, Carcereny E, Ahn MJ, Felip E, Lee JS, Hellmann MD, Hamid O, Goldman JW, Soria JC, Dolled-Filhart M, Rutledge RZ, Zhang J, Lunceford JK, Rangwala R, Lubiniecki GM, Roach C, Emancipator K, Gandhi L; KEYNOTE-001 Investigators.

N Engl J Med. 2015 May 21;372(21):2018-2028. Epub 2015 Apr 19.

11.

10-year long-term survival of a metastatic EGFR-mutated nonsmall cell lung cancer patient.

Kempf E, Planchard D, Le Chevalier T, Soria JC.

Eur Respir J. 2015 Apr 16. pii: ERJ-00173-2015. [Epub ahead of print] No abstract available.

PMID:
25882801
12.

High level of chromosomal instability in circulating tumor cells of ROS1-rearranged non-small-cell lung cancer.

Pailler E, Auger N, Lindsay CR, Vielh P, Islas-Morris-Hernandez A, Borget I, Ngo-Camus M, Planchard D, Soria JC, Besse B, Farace F.

Ann Oncol. 2015 Apr 6. pii: mdv165. [Epub ahead of print]

PMID:
25846554
13.

[Second generation ALK inhibitors in non-small cell lung cancer: Systemic review].

Viala M, Brosseau S, Planchard D, Besse B, Soria JC.

Bull Cancer. 2015 Apr;102(4):381-389. doi: 10.1016/j.bulcan.2015.02.016. Epub 2015 Mar 25. Review. French.

PMID:
25819217
14.

Comparative analysis of primary tumour and matched metastases in colorectal cancer patients: Evaluation of concordance between genomic and transcriptional profiles.

Vignot S, Lefebvre C, Frampton GM, Meurice G, Yelensky R, Palmer G, Capron F, Lazar V, Hannoun L, Miller VA, André F, Stephens PJ, Soria JC, Spano JP.

Eur J Cancer. 2015 May;51(7):791-9. doi: 10.1016/j.ejca.2015.02.012. Epub 2015 Mar 18.

PMID:
25797355
15.

[The genetics of thrombosis in cancer].

Soria JM, López S.

Med Clin (Barc). 2015 Jan;144 Suppl 1:26-30. doi: 10.1016/S0025-7753(15)30015-4. Spanish.

PMID:
25771089
16.

Phase I trial of everolimus in combination with thoracic radiotherapy in non-small-cell lung cancer.

Deutsch E, Le Péchoux C, Faivre L, Rivera S, Tao Y, Pignon JP, Angokai M, Bahleda R, Deandreis D, Angevin E, Hennequin C, Besse B, Levy A, Soria JC.

Ann Oncol. 2015 Feb 20. pii: mdv105. [Epub ahead of print]

PMID:
25701455
17.

VEGF-A Expression Correlates with TP53 Mutations in Non-Small Cell Lung Cancer: Implications for Antiangiogenesis Therapy.

Schwaederlé M, Lazar V, Validire P, Hansson J, Lacroix L, Soria JC, Pawitan Y, Kurzrock R.

Cancer Res. 2015 Apr 1;75(7):1187-90. doi: 10.1158/0008-5472.CAN-14-2305. Epub 2015 Feb 11.

PMID:
25672981
18.

Phase I dose-escalation study of pilaralisib (SAR245408, XL147), a pan-class I PI3K inhibitor, in combination with erlotinib in patients with solid tumors.

Soria JC, LoRusso P, Bahleda R, Lager J, Liu L, Jiang J, Martini JF, Macé S, Burris H.

Oncologist. 2015 Mar;20(3):245-6. doi: 10.1634/theoncologist.2014-0449. Epub 2015 Feb 10.

19.

Economic analysis of thrombo inCode, a clinical-genetic function for assessing the risk of venous thromboembolism.

Rubio-Terrés C, Soria JM, Morange PE, Souto JC, Suchon P, Mateo J, Saut N, Rubio-Rodríguez D, Sala J, Gracia A, Pich S, Salas E.

Appl Health Econ Health Policy. 2015 Apr;13(2):233-42. doi: 10.1007/s40258-015-0153-x.

20.

Debio0932, a second-generation oral heat shock protein (HSP) inhibitor, in patients with advanced cancer-results of a first-in-man dose-escalation study with a fixed-dose extension phase.

Isambert N, Delord JP, Soria JC, Hollebecque A, Gomez-Roca C, Purcea D, Rouits E, Belli R, Fumoleau P.

Ann Oncol. 2015 May;26(5):1005-11. doi: 10.1093/annonc/mdv031. Epub 2015 Feb 2.

PMID:
25646368
Format
Items per page
Sort by

Send to:

Choose Destination

Supplemental Content

Write to the Help Desk